WT1 and Hodgkins lymphoma: In fact, a recent trial in HL looked at exactly this approach, though instead of CAR T cells, the authors utilized polyclonal autologous or allogeneic T cells expanded ex vivo to recognize a number of novel target antigens in HL, including WT1, Survivin, and PRAME [72].